MB-111
Undisclosed
PreclinicalActive
Key Facts
About Mammoth Biosciences
Mammoth Biosciences, founded in 2017 and co-founded by CRISPR pioneer Jennifer Doudna, is a private biotech developing a next-generation CRISPR platform. The company's core innovation lies in discovering and engineering novel, ultracompact Cas enzymes (like its NanoCas systems) designed to overcome the delivery bottlenecks of in vivo gene editing, particularly for extrahepatic tissues. With a pipeline advancing towards the clinic, strategic partnerships, and a dual focus on therapeutics and diagnostics, Mammoth aims to unlock the full potential of genetic medicine.
View full company profileOther Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |